-
1
-
-
0025605056
-
Evidence for an epidermal cytokine network
-
Luger TA, Schwarz T. Evidence for an epidermal cytokine network. J Invest Dermatol 1990; 95: 100S-104S.
-
(1990)
J Invest Dermatol
, vol.95
-
-
Luger, T.A.1
Schwarz, T.2
-
3
-
-
0002831954
-
Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy
-
Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. J Clin Oncol 1996; 14:7-17.
-
(1996)
J Clin Oncol
, vol.14
, pp. 7-17
-
-
Legha, S.S.1
-
4
-
-
0034088027
-
High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
-
Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-58.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2444-2458
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sondak, V.K.3
-
5
-
-
0035339880
-
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
-
Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-80.
-
(2001)
J Clin Oncol
, vol.19
, pp. 2370-2380
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sosman, J.A.3
-
7
-
-
0032533917
-
Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II
-
Stadler R, Otte HG, Luger T et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-81.
-
(1998)
Blood
, vol.92
, pp. 3578-3581
-
-
Stadler, R.1
Otte, H.G.2
Luger, T.3
-
8
-
-
0030927592
-
Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma
-
Dippel E, Schrag H, Goerdt S, Orfanos CE. Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma. Lancet 1997; 350: 32-3.
-
(1997)
Lancet
, vol.350
, pp. 32-33
-
-
Dippel, E.1
Schrag, H.2
Goerdt, S.3
Orfanos, C.E.4
-
9
-
-
0032009981
-
HIV-1, HHV-8, and Kaposi's sarcoma
-
Gallo RC. HIV-1, HHV-8, and Kaposi's sarcoma. J Hum Virol 1998; 1: 185-6.
-
(1998)
J Hum Virol
, vol.1
, pp. 185-186
-
-
Gallo, R.C.1
-
10
-
-
0026018583
-
Long-term therapy of HIV-associated Kaposi's sarcoma with recombinant interferon alpha-2a
-
Schaart FM, Bratzke B, Ruszczak Z, Stadler R, Ehlers G, Orfanos CE. Long-term therapy of HIV-associated Kaposi's sarcoma with recombinant interferon alpha-2a. Br J Dermatol 1991; 124: 62-8.
-
(1991)
Br J Dermatol
, vol.124
, pp. 62-68
-
-
Schaart, F.M.1
Bratzke, B.2
Ruszczak, Z.3
Stadler, R.4
Ehlers, G.5
Orfanos, C.E.6
-
11
-
-
0033388527
-
Inhibition of angiogenesis by type I interferons in models of Kaposi's sarcoma
-
Marchisone C, Benelli R, Albini A, Santi L, Noonan DM. Inhibition of angiogenesis by type I interferons in models of Kaposi's sarcoma. Int J Biol Markers 1999; 14: 257-62.
-
(1999)
Int J Biol Markers
, vol.14
, pp. 257-262
-
-
Marchisone, C.1
Benelli, R.2
Albini, A.3
Santi, L.4
Noonan, D.M.5
-
12
-
-
0025083873
-
Intralesional interferon therapy for basal cell carcinoma
-
Cornell RC, Greenway HT, Tucker SB et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23: 694-700.
-
(1990)
J Am Acad Dermatol
, vol.23
, pp. 694-700
-
-
Cornell, R.C.1
Greenway, H.T.2
Tucker, S.B.3
-
13
-
-
0034948887
-
Human papillomavirus infections: Epidemiology, pathogenesis, and therapy
-
Severson J, Evans TY, Lee P, Chan TS, Arany I, Tyring SK. Human papillomavirus infections: Epidemiology, pathogenesis, and therapy. J Cutan Med Surg 2001; 5: 43-60.
-
(2001)
J Cutan Med Surg
, vol.5
, pp. 43-60
-
-
Severson, J.1
Evans, T.Y.2
Lee, P.3
Chan, T.S.4
Arany, I.5
Tyring, S.K.6
-
14
-
-
2642712490
-
Therapy of human papillomavirus infection and associated epithelial tumors
-
Gross G. Therapy of human papillomavirus infection and associated epithelial tumors. Intervirology 1997; 40: 368-77.
-
(1997)
Intervirology
, vol.40
, pp. 368-377
-
-
Gross, G.1
-
15
-
-
0033490481
-
Therapeutic perspectives in atopic dermatitis
-
Leung DYM. Therapeutic perspectives in atopic dermatitis. Allergy 1999; 58: 39-42.
-
(1999)
Allergy
, vol.58
, pp. 39-42
-
-
Leung, D.Y.M.1
-
16
-
-
0032868081
-
Pathogenesis of atopic dermatitis
-
Leung DYM. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999; 104: 99-108.
-
(1999)
J Allergy Clin Immunol
, vol.104
, pp. 99-108
-
-
Leung, D.Y.M.1
-
17
-
-
0031873870
-
Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels
-
Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998; 134: 799-804.
-
(1998)
Arch Dermatol
, vol.134
, pp. 799-804
-
-
Stevens, S.R.1
Hanifin, J.M.2
Hamilton, T.3
Tofte, S.J.4
Cooper, K.D.5
-
18
-
-
0031941774
-
Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis
-
Schneider LC, Baz Z, Zarcone C, Zurakowski D. Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. Ann Allergy Asthma Immunol 1998; 80: 263-8.
-
(1998)
Ann Allergy Asthma Immunol
, vol.80
, pp. 263-268
-
-
Schneider, L.C.1
Baz, Z.2
Zarcone, C.3
Zurakowski, D.4
-
19
-
-
0034489868
-
Systemic therapy of atopic dermatitis
-
Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin Exp Dermatol 2000; 25: 559-66.
-
(2000)
Clin Exp Dermatol
, vol.25
, pp. 559-566
-
-
Sidbury, R.1
Hanifin, J.M.2
-
20
-
-
0032432952
-
Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis
-
Noh GW, Lee KY. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy 1998; 53: 1202-7.
-
(1998)
Allergy
, vol.53
, pp. 1202-1207
-
-
Noh, G.W.1
Lee, K.Y.2
-
21
-
-
0028266553
-
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
-
Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907-13.
-
(1994)
JAMA
, vol.271
, pp. 907-913
-
-
Rosenberg, S.A.1
Yang, J.C.2
Topalian, S.L.3
-
22
-
-
17744388962
-
Dacarbazine and interferon alpha with or without interleukin 2 in meta-static melanoma: A randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
-
Hauschild A, Garbe C, Stolz W et al. Dacarbazine and interferon alpha with or without interleukin 2 in meta-static melanoma: A randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 2001; 84: 1036-42.
-
(2001)
Br J Cancer
, vol.84
, pp. 1036-1042
-
-
Hauschild, A.1
Garbe, C.2
Stolz, W.3
-
23
-
-
0035831628
-
Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study
-
Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study. Hum Gene Ther 2001; 12: 671-84.
-
(2001)
Hum Gene Ther
, vol.12
, pp. 671-684
-
-
Kang, W.K.1
Park, C.2
Yoon, H.L.3
Kim, W.S.4
Yoon, S.S.5
Lee, M.H.6
-
25
-
-
0002979775
-
IL-4-induced immune deviation as therapy of psoriasis
-
Thomas P. IL-4-induced immune deviation as therapy of psoriasis. Arch Derm Res 2001; 293: 39.
-
(2001)
Arch Derm Res
, vol.293
, pp. 39
-
-
Thomas, P.1
-
26
-
-
0033505875
-
Interleukin-10 in cutaneous disorders: Implications for its pathophysiological importance and therapeutic use
-
Asadullah K, Sabat R, Wiese A, Docke WD, Volk HD, Sterry W. Interleukin-10 in cutaneous disorders: Implications for its pathophysiological importance and therapeutic use. Arch Dermatol Res 1999; 291: 628-36.
-
(1999)
Arch Dermatol Res
, vol.291
, pp. 628-636
-
-
Asadullah, K.1
Sabat, R.2
Wiese, A.3
Docke, W.D.4
Volk, H.D.5
Sterry, W.6
-
28
-
-
0032519956
-
IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach
-
Asadullah K, Sterry W, Stephanek K et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach. J Clin Invest 1998; 101: 783-94.
-
(1998)
J Clin Invest
, vol.101
, pp. 783-794
-
-
Asadullah, K.1
Sterry, W.2
Stephanek, K.3
-
29
-
-
0345251966
-
Interleukin 10 treatment of psoriasis: Clinical results of a phase 2 trial
-
Asadullah K, Döcke WD, Ebeling M et al. Interleukin 10 treatment of psoriasis: Clinical results of a phase 2 trial. Arch Dermatol 1999; 135: 187-92.
-
(1999)
Arch Dermatol
, vol.135
, pp. 187-192
-
-
Asadullah, K.1
Döcke, W.D.2
Ebeling, M.3
-
30
-
-
0032458296
-
Treatment of psoriasis with Interleukin-10
-
Reich K, Bruck M, Grafe A, Vente C, Neumann C, Garbe C. Treatment of psoriasis with Interleukin-10. J Invest Dermatol 1998; 6: 1235-6.
-
(1998)
J Invest Dermatol
, vol.6
, pp. 1235-1236
-
-
Reich, K.1
Bruck, M.2
Grafe, A.3
Vente, C.4
Neumann, C.5
Garbe, C.6
-
31
-
-
0012948856
-
Effects of systemic interleukin-10 therapy on psoriatic skin lesions: Histological, immunohistological and molecular biological findings
-
Asadullah K, Friedrich M, Hanneken S et al. Effects of systemic interleukin-10 therapy on psoriatic skin lesions: Histological, immunohistological and molecular biological findings. J Invest Dermatol 2001; 116: 721-7.
-
(2001)
J Invest Dermatol
, vol.116
, pp. 721-727
-
-
Asadullah, K.1
Friedrich, M.2
Hanneken, S.3
-
32
-
-
0035113406
-
Response of Psoriasis to Interleukin-10 is Associated with Suppression of Cutaneous Type 1 Inflammation, Downregulation of the Epidermal Interleukin-8/CXCR2 Pathway and Normalization of Keratinocyte Maturation
-
Reich K, Garbe C, Blaschke V et al. Response of Psoriasis to Interleukin-10 is Associated with Suppression of Cutaneous Type 1 Inflammation, Downregulation of the Epidermal Interleukin-8/CXCR2 Pathway and Normalization of Keratinocyte Maturation. J Invest Dermatol 2001; 116: 319-29.
-
(2001)
J Invest Dermatol
, vol.116
, pp. 319-329
-
-
Reich, K.1
Garbe, C.2
Blaschke, V.3
-
33
-
-
0033404492
-
Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions
-
Trepicchio WL, Ozawa M, Walters IB et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104: 1527-37.
-
(1999)
J Clin Invest
, vol.104
, pp. 1527-1537
-
-
Trepicchio, W.L.1
Ozawa, M.2
Walters, I.B.3
-
34
-
-
0032695429
-
Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicenter randomized phase II study
-
Lienard D, Eggermont AM, Koops HS et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicenter randomized phase II study. Melanoma Res 1999; 9: 491-502.
-
(1999)
Melanoma Res
, vol.9
, pp. 491-502
-
-
Lienard, D.1
Eggermont, A.M.2
Koops, H.S.3
|